As inhibition with pan TGF-β neutralizing antibodies is likely to induce side effects, aortic aneurysms associated with increased TGF-β2 might benefit from a TGF-β2 specific intervention decreasing systemic side effects by targeting the other isoforms. The gene discussed is TGFB2; the disease is aortic aneurysm.